Please provide your email address to receive an email when new articles are posted on . Men with low- or intermediate-risk prostate cancer achieved similar quality-of-life outcomes whether they ...

Anemia and low performance status predict worse survival and greater risk for treatment failure in low-intermediate risk vs low-risk patients with mRCC treated with first-line ICI-based therapy.

The Food and Drug Administration has approved Rytelo to treat certain patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia. The Food and Drug Administration (FDA) has ...

Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...

Graphical Abstract. Relative survival with and without radioiodine therapy (RAI) in intermediate risk papillary thyroid cancer (PTC) and low risk, minimally invasive follicular thyroid cancer (FTC). A ...

Presents 18-month duration of response (DOR) data from the ENVISION study Analyzes the impact of tumor burden or focality in recurrent LG-IR-NMIBC, a substudy from ENVISION Reports ENVISION and ATLAS ...